Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Accounts Payables: 2010-2024

Historic Accounts Payables for Ligand Pharmaceuticals (LGND) over the last 15 years, with Dec 2024 value amounting to $5.2 million.

  • Ligand Pharmaceuticals' Accounts Payables fell 21.62% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year decrease of 21.62%. This contributed to the annual value of $5.2 million for FY2024, which is 115.62% up from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Accounts Payables stood at $5.2 million for FY2024, which was up 115.62% from $2.4 million recorded in FY2023.
  • Ligand Pharmaceuticals' 5-year Accounts Payables high stood at $8.4 million for FY2021, and its period low was $2.4 million during FY2023.
  • Its 3-year average for Accounts Payables is $4.3 million, with a median of $5.2 million in 2024.
  • Its Accounts Payables has fluctuated over the past 5 years, first surged by 122.07% in 2021, then tumbled by 54.27% in 2023.
  • Over the past 5 years, Ligand Pharmaceuticals' Accounts Payables (Yearly) stood at $3.8 million in 2020, then soared by 122.07% to $8.4 million in 2021, then slumped by 36.84% to $5.3 million in 2022, then plummeted by 54.27% to $2.4 million in 2023, then surged by 115.62% to $5.2 million in 2024.